References
- Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019;104(9):1710–1719.
- Leite ACCB, de Oliveira RVC, de Moura PG, et al. Abnormal transcranial Döppler ultrasonography in children with sickle cell disease. Rev Bras Hematol Hemoter. 2012;34(4):307–310.
- Belisário AR, Carneiro-Proietti AB, Sabino EC, et al. Hb S/β-Thalassemia in the REDS-III Brazil sickle cell disease cohort: clinical, laboratory and molecular characteristics. Hemoglobin [Internet]. 2020;44(1):1–9.
- Belisário AR, Sales RR, Viana MB. Very mild forms of Hb S/beta+-thalassemia in Brazilian children. Rev Bras Hematol Hemoter. 2015;37(3):198–201.
- Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. The Lancet 2017;390(10091):311–323.
- Power-Hays A, Ware RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Curr Opin Hematol. 2020;27(3):172–180.
- Adebiyi MG, Manalo JM, Xia Y. Metabolomic and molecular insights into sickle cell disease and innovative therapies. Blood Adv. 2019;3(8):1347–1355.
- Tisdale JF, Thein SL, Eaton WA. Treating sickle cell anemia. Science. 2020;367(6483):1198–1199.
- Dong M, McGann PT. Changing the clinical paradigm of hydroxyurea treatment for sickle cell anemia through precision medicine. Clin Pharmacol Ther. 2021;109(1):73–81.
- Steinberg MH. Treating sickle cell anemia: a new era dawns. Am J Hematol. 2020;95(4):338–342.
- Yesilipek MA. Hematopoietic stem cell transplantation in patients with hemoglobinopathies. Hemoglobin. 2020;44(6):377–384.
- Gratwohl A, Baldomero H, Frauendorfer K, et al. Why are there regional differences in stem cell transplantation activity? An EBMT analysis. Bone Marrow Transplant. 2008;42(S1):S7–S10.
- Piccin A, Murphy C, Eakins E, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol. 2019;102(4):319–330.
- Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):18010.
- Conran N, Torres L. cGMP modulation therapeutics for sickle cell disease. Exp Biol Med (Maywood). 2019;244(2):132–146.
- Wen J, Jiang X, Dai Y, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. Faseb J. 2010;24(3):740–749.
- Hu X, Adebiyi MG, Luo J, et al. Sustained elevated adenosine via ADORA2B promotes chronic pain through neuro-immune interaction. Cell Rep. 2016;16(1):106–119.
- Sun K, D'Alessandro A, Ahmed MH, et al. Structural and functional insight of sphingosine 1-phosphate-mediated pathogenic metabolic reprogramming in sickle cell disease. Sci Rep. 2017;7(1):15281.
- Zhao S, Adebiyi MG, Zhang Y, et al. Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease. Faseb J. 2018;32(5):2855–2865.
- Allali S, Maciel TT, Hermine O, et al. Innate immune cells, major protagonists of sickle cell disease pathophysiology. Haematologica. 2020;105(2):273–283.
- Andrieu-Soler C, Soler E. When basic science reaches into rational therapeutic design: from historical to novel leads for the treatment of β-globinopathies. Curr Opin Hematol. 2020;27(3):141–148.
- Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39(10):1197–1199.
- Biassi TP, Guerra-Shinohara EM, Moretti PNS, et al. miRNA profile and disease severity in patients with sickle cell anemia. Ann Hematol. 2022;101(1):27–34.
- Sangokoya C, LaMonte G, Chi J-T. Isolation and characterization of MicroRNAs of human mature erythrocytes. Methods Mol Biol. 2010; 667:193–203.
- Verma HK, Ratre YK, Bhaskar LVKS, et al. Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy. Ann Hematol. 2021;100(3):607–614.
- Mnika K, Mazandu GK, Jonas M, et al. Hydroxyurea-induced miRNA expression in sickle cell disease patients in Africa. Front Genet. 2019;10:509.
- Cyrus C. The role of miRNAs as therapeutic tools in sickle cell disease. Medicina. 2021;57(10):1106.
- Starlard-Davenport A, Fitzgerald A, Pace BS. Exploring epigenetic and microRNA approaches for γ-globin gene regulation. Exp Biol Med. 2021;246(22):2347–2357.
- Ginder GD. Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res. 2015;165(1):115–125.
- Matte A, Cappellini MD, Iolascon A, et al. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment? Expert Opin Investig Drugs. 2020;29(1):23–31.
- Elenga N, Loko G, Etienne-Julan M, et al. Real-world data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients. Front Med (Lausanne)). 2022;9:931925.
- Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 2019;18(2):139–158.
- Niihara Y, Zerez CR, Akiyama DS, et al. Oral L-glutamine therapy for sickle cell anemia: I. subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 1998;58(2):117–121.
- Quinn CT. l-Glutamine for sickle cell anemia: more questions than answers. Blood [Internet]. 2018;132(7):689–693.
- Sadaf A, Quinn CT. L-glutamine for sickle cell disease: Knight or pawn? Exp Biol Med. 2020;245(2):146–154.
- Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235.
- Center for drug evaluation and, research, FDA. Endari/L-glutamine powder. Summary Review [Internet]. [cited 2022 Mar 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208587Orig1s000SumR.pdf.
- Engel ER, Howard AL, Ankus EJ, et al. Advances in sickle cell disease management. Adv Pediatr. 2020;67:57–71.
- Herity LB, Vaughan DM, Rodriguez LR, et al. Voxelotor: a novel treatment for sickle cell disease. Ann Pharmacother. 2021;55(2):240–245.
- Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519.
- Oxbryta (Voxelotor) prescribing-information [Internet]. [cited 2022 Mar 28]. Available from: https://www.oxbryta.com/pdf/prescribing-information.pdf.
- Estepp JH, Kalpatthi R, Woods G, et al. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatr Blood Cancer. 2022;69(8):e29716.
- Blair HA. Crizanlizumab: First Approval. Drugs. 2020;80(1):79–84.
- Novartis Biociências SA. Adakveo. Bula Profissional [Internet]. 2022 [cited 2022 Apr 7]. Available from: https://buladeremedio.net/pdfs/adakveo_2802812022_1648839100438-repaired.pdf.
- Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
- Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019;94(1):55–61. [cited 2022 Mar 4]Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25308.
- Thom H, Jansen J, Shafrin J, et al. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. BMJ Open. 2020;10(9):e034147.
- Benites BD, Olalla-Saad ST. An update on arginine in sickle cell disease. Expert Rev Hematol. 2019;12(4):235–244.
- Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294(1):81–90.
- Onalo R, Cooper P, Cilliers A, et al. Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol. 2021;96(1):89–97.
- Anvisa aprova medicamentos inéditos para asma, hipertensão pulmonar e tumor cerebral [Internet]. Agência Nacional de Vigilância Sanitária - Anvisa. [cited 2022 Apr 11]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/anos-anteriores/anvisa-aprova-medicamentos-ineditos-para-asma-hipertensao-pulmonar-e-tumor-cerebral.
- Frey R, Saleh S, Becker C, et al. Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ. 2016;6(Suppl 1):S58–S65.
- Weir NA, Conrey A, Lewis D, et al. Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series. Pulm Circ. 2018;8(4):2045894018791802.
- Charnigo RJ, Beidler D, Rybin D, et al. PF‐04447943, a phosphodiesterase 9A inhibitor, in stable sickle cell disease patients: a phase ib randomized, placebo‐controlled study. Clin Transl Sci. 2019;12(2):180–188.
- Ribeiro-Filho J, Yahouédéhou SCMA, Pitanga TN, et al. An evaluation of ticagrelor for the treatment of sickle cell anemia. Expert Rev Hematol. 2020;13(10):1047–1055.
- Brilinta® (Ticagrelor): nova indicação [Internet]. Agência Nacional de Vigilância Sanitária - Anvisa. [cited 2022 Apr 11]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/brilinta-nova-indicacao.
- Hsu LL, Sarnaik S, Williams S, et al. A dose‐ranging study of ticagrelor in children aged 3‐17 years with sickle cell disease: a 2‐part phase 2 study. Am J Hematol. 2018;93(12):1493–1500.
- Kanter J, Abboud MR, Kaya B, et al. Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Br J Haematol. 2019;184(2):269–278.
- Klei TRL, Dalimot JJ, Beuger BM, et al. The Gardos effect drives erythrocyte senescence and leads to Lu/BCAM and CD44 adhesion molecule activation. Blood Adv. 2020;4(24):6218–6229.
- Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008;111(8):3991–3997.
- Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). Br J Haematol. 2011;153(1):92–104.
- Ataga KI, Staffa SJ, Brugnara C, et al. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial. Br J Haematol. 2021;192(5):e129–e132.
- Chabner BA, Koop CE, Niederhuber JE, et al. Homage to Judah Folkman. The Oncologist [Internet]. 2008;13(2):205–211.
- Telen MJ. Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events? Blood Adv. 2020;4(14):3457–3465.
- Sickle Cell Disease - List Results - ClinicalTrials.gov [Internet]. [cited 2022 Mar 28]. Available from: https://clinicaltrials.gov/ct2/results?cond=Sickle+Cell+Disease&term=&type=Intr&rslt=&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&phase=4&phase=0&phase=1&phase=2&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=.
- High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455–464.
- Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–260.
- Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386(7):617–628.
- Molokie R, Lavelle D, Gowhari M, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 2017;14(9):e1002382.
- Berdeja JG, Laubach JP, Richter J, et al. Panobinostat from bench to bedside: rethinking the treatment paradigm for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(11):752–765.
- Rai P, Ataga KI. Drug therapies for the management of sickle cell disease. F1000Res. 2020;9:592.
- Nur E, Brandjes DP, Teerlink T, et al. N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann Hematol. 2012;91(7):1097–1105.
- Rab MAE, Bos J, van Oirschot BA, et al. Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. Blood. 2021;137(21):2997–3001.
- Al-Samkari H, van Beers EJ. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias. Ther Adv Hematol. 2021;12:20406207211066070.
- van Dijk MJ, Rab MAE, van Oirschot BA, et al. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label study. American J Hematol. 2022;97(7):E226–E229.
- Shah F, Dwivedi M. Pathophysiology and recent therapeutic insights of sickle cell disease. Ann Hematol. 2020;99(5):925–935.
- Monus T, Howell CM. Current and emerging treatments for sickle cell disease. JAAPA. 2019;32(9):1–5.
- Hoppe C, Neumayr L. Sickle cell disease: monitoring, current treatment, and therapeutics under development. Hematol Oncol Clin North Am. 2019;33(3):355–371.
- Leibovitch JN, Tambe AV, Cimpeanu E, et al. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: hype or hope? Blood Rev. 2022; 53:100925.
- Park SH, Bao G. CRISPR/Cas9 gene editing for curing sickle cell disease. Transfus Apher Sci. 2021;60(1):103060.
- Thornburg CD, Calatroni A, Telen M, et al. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156(3):415–419.
- Adams-Graves P, Bronte-Jordan L. Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence. Expert Rev Hematol. 2016;9(6):541–552.
- Santos A. R R d, Miyazaki M. C d O. Grupo de sala de espera em ambulatório de doença falciforme. Rev Bras Ter Comp Cogn. 1999;1(1):41–48.
- Cecilio SG, Pinto VDS, Pereira SADS, et al. Instrumentos de mensuração relacionados ao conhecimento, adesão, atitude e autoeficácia em doença falciforme: revisão integrativa. Cogitare Enferm. 2019;24:24.